July 3, 2019
Takeda Pharmaceutical said on July 1 that it has completed the sale of its dry eye treatment Xiidra (lifitegrast) to Novartis for US$3.4 billion upfront. Under the deal, the Japanese giant is also entitled to receive potential milestone payments of...read more